Healthcare Business

Raymond James Top Health Care Picks Crushing S&P 500: 4 Stocks to Buy Now

CVS completed a $69 billion purchase of health care provider Aetna in November of 2018 and remains one of the top picks for 2021 and beyond, as CVS has become one of the most vertically integrated publicly traded health care companies

Investors receive a 2.87 % dividend. The Raymond James price target is $90, while the posted consensus target was last seen at $81.71. CVS Health stock closed Wednesday’s trading at $69.63 per share, after a solid 3% gain on the day.

Healthcare Realty Trust

This medical real estate investment trust (REIT) has pulled back recently after a big move and is an outstanding idea for conservative investors looking for sector exposure and income. Healthcare Realty Trust Inc. (NYSE: HR) integrates owning, managing, financing and developing income-producing real estate properties associated primarily with the delivery of outpatient health care services throughout the United States.

As of March 31, 2020, the company owned 212 real estate properties in 25 states, totaling 15.8 million square feet, and was valued at approximately $5.3 billion. The company provided leasing and property management services to 12.0 million square feet nationwide.

Investors receive a very solid 4.05% distribution. The $35 Raymond James price objective compares to a posted consensus target price of $31.58. Healthcare Realty Trust stock closed at $29.55 on Wednesday.

UniQure

This is an off-the-radar idea for investors who are more aggressive. UniQure N.V. (NASDAQ: QURE) is a gene therapy company that engages in the development and commercialization of treatments for patients suffering from genetic and other diseases in the Netherlands. Its lead program is Etranacogene dezaparvovec (AMT-061), which is in Phase 3 HOPE-B pivotal trial for the treatment of hemophilia B.

The company also engages in developing the following:

  • AMT-130, a gene therapy that is in Phase 1 and 2 clinical study for the treatment of Huntington’s disease
  • AMT-060, which is in Phase 1 and 2 clinical trials for the treatment of hemophilia B
  • AMT-180, a one-time intravenously administered gene therapy candidate, which is in preclinical stage for the treatment of hemophilia A
  • AMT-190, an IV-administered adeno-associated virus 5-based gene therapy for the treatment of Fabry disease

The Raymond James analysts have a $75 price objective. The consensus target price is $70.67, and the final closing print for UniQure stock on Wednesday was $50.67 a share.


These are four of the highest-ranked health care ideas from the Raymond James Top Picks list. Two of them that are ideal for more conservative investors who are looking to add plays in the sector but would like to avoid the risk of clinical disappointments. All these companies look poised for a strong 2021 and their shares merit some strong consideration.

Sponsored: Find a Qualified Financial Advisor:

Finding a qualified financial advisor doesn’t have to be hard. SmartAsset’s free tool matches you with up to 3 fiduciary financial advisors in your area in 5 minutes. Each advisor has been vetted by SmartAsset and is held to a fiduciary standard to act in your best interests. If you’re ready to be matched with local advisors that can help you achieve your financial goals, get started now.